1 tracked superinvestor hold GAIN THERAPEUTICS INC (GANX), worth $1M combined, led by David Einhorn. Smart money is holding GANX as of the latest 13F filings.
Current price
$1.80
+4.0%
1Y
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed…
Market cap
$79M
P/E
-3.08
Div yield
—
Revenue YoY
—
Analyst target
—
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$1M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding GANX steady this quarter — buys and sells are balanced.
GAIN THERAPEUTICS INC (GANX) is held by 1 tracked funds worth $1M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to David Einhorn at 0% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0% | $1M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own GANX?
1 tracked funds hold GAIN THERAPEUTICS INC (GANX), the largest being David Einhorn (Greenlight Capital) at 0% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling GANX?
In the most recent 13F quarter, 0 tracked funds added or opened GANX and 0 trimmed it.
How much GANX do tracked funds hold?
Combined disclosed long exposure to GANX across tracked superinvestors is $1M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.